The Geron Corporation announced that the first patient has been dosed with GRN163L — an experimental agent — in a phase 3 clinical trial to assess the drug’s overall survival benefit compared to best available therapy in patients with refractory myelofibrosis.
Treatment with a novel therapy as a single agent, or in combination with Venclexta, demonstrated a manageable safety profile and antileukemic effects in patients with relapsed/refractory acute myeloid leukemia. The study authors, however, note that more research is needed.
A woman with metastatic breast cancer describes the overwhelming dread she feels every time she must wait to hear the results of a tumor marker test.
Prior to the program, patients with hematologic cancers walked an average of 136 steps in a 24-hour period. One month after the program began, that total increased to an average of 1,018 steps per day.
Treatment with daily Jakafi and parsaclisib improved spleen volume reduction and symptom burden in patients with myelofibrosis who had previously failed to achieve significant response to single-agent Jakafi.
A gynecologic oncologist who has spent her career helping patients during their cancer journeys goes a step further to educate women on how to advocate for themselves and possibly prevent cancer before it occurs.
On social media, CURE® recently asked its readers with rare cancers what advice they would offer to fellow patients with a similar diagnosis. Here’s what they shared.
"Some experiences we have as cancer survivors may help inspire those reluctant to get or complete COVID-19 vaccinations to follow through. We are all role models for each other."
Twenty percent of patients with resectable hepatocellular carcinoma had a significant amount of cell death when receiving Libtayo before surgical intervention.
There is a difference between patient and oncologists regarding prognosis, and patients are lacking understanding of prognosis and interventions needed to help them make more informed treatment choices.
A mother and caregiver describes how she views each moment with her daughter differently after her daughter’s breast cancer diagnosis.
Sophisticated analyses can predict which gut microbiome profile may lead to better outcomes to immunotherapy for patients with advanced melanoma.
Cancer survivors have the responsibility of sharing their knowledge of living in the world of cancer with the newly diagnosed, writes one survivor. Here, she shares ways to offer help.
Today is World Ovarian Cancer Day, and in honor of this day that was created in 2013 to raise awareness about the disease, CURE® is rounding up the latest news and updates in this cancer space.
Interim results from a phase 2 study demonstrated that patients inoperable or advanced intrahepatic cholangiocarcoma and a FGFR2 gene mutation had a disease control rate of 79% when treated with derazantinib.
Luckily, obtaining a second opinion has become easier with advances in telehealth and other virtual technologies, which allow patients to share their medical records and test results with physicians and pathologists to potentially improve treatment plans.
A melanoma survivor pens a poem about his cancer journey, losing his wife to melanoma and how he lives his life after these experiences.
From a 114-year-old cancer survivor breaking records to an operating room nurse giving birth to a cancer survivor’s baby, here’s what’s happening in the cancer landscape this week.
Patients with melanoma treated with Keytruda had improved recurrence-free survival without an effect on their quality of life.
Compared to a hypomethylating agent alone, combining the agent with Venclexta improved complete remission rates in patients with blast-phase myeloproliferative neoplasm.
Members of an FDA committee voted in favor of Tecentriq plus Abraxane keeping its accelerated approval for the treatment of adults with unresectable, locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.
“We’re all blessed that there are so many dedicated, caring health care professionals willing to step in and fill the void when members of the team move or retire,” writes a patient with cancer. “We can never forget how tough a gig it is or say thank you enough.”
In this episode of the “CURE® Talks Cancer” podcast, Leanne Burnham, Ph.D., discusses the research she’s working on to address health disparities in Black men with prostate cancer after being inspired by her father’s diagnosis, and shares her own cancer survival story.
The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.
Virtual visits during the COVID-19 pandemic improved satisfaction and convenience, as well as reduced stress and anxiety in veterans who have survived cancer.
FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.
Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.
Women who receive a breast cancer diagnosis were more likely to develop unhealthy behaviors one and two years after diagnosis, even if they were considered healthy at time of diagnosis.
A cancer survivor recalls how a book quote about a blizzard became a metaphor for her own experiences with cancer.
Patients with cancer should receive whichever COVID-19 vaccine is made available to them as the benefits far outweigh the risks, according to an expert from Memorial Sloan Kettering Cancer Center.
